Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Heltzen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Beta
- 3.19
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.98
Financials
Net Income
$-2.88MEBITDA
$-3.03MFree Cash Flow
$-1.64MEPS (diluted)
$-0.33Shares Outstanding (diluted)
8.66M+6.6%Operating Expenses
$2.95MCash & Debt
$5.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-9.16M | $-1.09 |
| 2024 | $0.00 | $-5.86M | $-0.72 |
| 2023 | $0.00 | $-2.04M | $-0.25 |
| 2022 | $0.00 | $-1.40M | $-0.17 |
| 2021 | $0.00 | $-1.21M | $-0.15 |
Valuation
EXOZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (6)
- Newsthenewswire.com·3d ago·Negative
…ty" October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity”. The report can be accessed here. eXoZymes, Inc. (NASDAQ: EXOZ) develops cell-free biomanufacturing systems that use engineered enzymes, or “exozymes”, to produce molecules outside living cells. Emerging from UCLA research, the company…
View source ↗ - Newsaccessnewswire.com·27d ago·Neutral
… commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technology The agreement represents the next major step i…
View source ↗ - Newsmarketbeat.com·46d ago·Neutral
eXoZymes Q2 Earnings Call Highlights eXoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.
View source ↗ - Newsaccessnewswire.com·46d ago·Neutral
…pdate at 5PM ET Today Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.
View source ↗ - Newsaccessnewswire.com·48d ago·Negative
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
View source ↗ - Newsaccessnewswire.com·55d ago·Neutral
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Estimates and results for EXOZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EXOZ officers and directors.
- Bought
- $17k
- Sold
- $15k
6 trades
2 trades
- Heltzen Michaelbought
- Heltzen Michaelbought
- Heltzen Michaelbought
- Heltzen Michaelbought
- Heltzen Michaelbought
- Korman Tyler Pazsold
- Korman Tyler Pazsold
- Heltzen Michaelbought
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EXOZ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.